Onderneming Apricus Biosciences Inc Nasdaq
Aandelen
US03832V3078
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Pharmaceutical Products
100,0
%
| 0 | nan % | 2 | 100,0 % | - |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 0 | nan % | 2 | 100,0 % | - |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Raj Mehra
CEO | Chief Executive Officer | 64 | 01-01-87 |
Director of Finance/CFO | 52 | 01-01-19 | |
Karen Fusaro
CTO | Chief Tech/Sci/R&D Officer | - | - |
Gopal Krishna
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | 66 | - | |
Anthony Marciano
IRC | Investor Relations Contact | - | 01-08-17 |
Lucas Pilipski
PRN | Corporate Officer/Principal | - | 01-12-20 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 77 | 01-09-21 | |
Richard Pascoe
CHM | Chairman | 60 | 01-03-13 |
Daniel O'Connor
BRD | Director/Board Member | 59 | 01-01-19 |
Brian Lian
BRD | Director/Board Member | 58 | 01-01-19 |
Raj Mehra
CEO | Chief Executive Officer | 64 | 01-01-87 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 16 609 128 | 16 335 242 ( 98,35 %) | 0 | 98,35 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
REGNUM CORP. 98.82% | 22 680 000 | 98.82% | 725 760 $ |
Bedrijfsgegevens
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+5,33% | 111 mld. | |
+12,11% | 106 mld. | |
-12,56% | 22,24 mld. | |
-3,29% | 21,25 mld. | |
-5,71% | 18,97 mld. | |
-35,21% | 18,52 mld. | |
-10,86% | 16,81 mld. | |
+37,57% | 12,54 mld. | |
-26,24% | 8,09 mld. |